Latest News for: sarepta

Edit

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

The Galveston Daily News 24 Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2026-- ....
Edit

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

The Galveston Daily News 24 Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2026-- ....
Edit

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (Sarepta Therapeutics Inc)

Public Technologies 13 Feb 2026
). The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete ... Washington, D.C. 20549. FORM 13F ... OMB APPROVAL ... Sarepta Therapeutics, Inc ... Sarepta Therapeutics Inc.
Edit

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

The Milton Standard Journal 11 Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2026-- ....
Edit

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

Business Wire 04 Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc ... Sarepta expects to initiate this ...
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Sarepta Therapeutics Inc)

Public Technologies 30 Jan 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 0.5 ... 2 ... Sarepta Therapeutics, Inc ... 6 ... Sarepta Therapeutics Inc.
Edit

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key ...

The Galveston Daily News 26 Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 26, 2026-- ....
Edit

Sarepta Therapeutics (SRPT) Stock: Investors Brace for Pivotal Monday Data Release

BitRSS 26 Jan 2026
TLDR Sarepta Therapeutics announces January 26 release of 3-year EMBARK study data for Elevidys gene therapy at 8.30 am ET Stock dropped 3% to $21.13 Friday but surged 5% after hours to $22.20 on the announcement FDA restricted Elevidys... .
Edit

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (Sarepta Therapeutics Inc)

Public Technologies 26 Jan 2026
23, 2026-- Sarepta Therapeutics, Inc ... About Sarepta Therapeutics. Sarepta is on an urgent mission ... We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com ... [email protected].
Edit

Sarepta EMBARK 3 Year Topline Results (Sarepta Therapeutics Inc)

Public Technologies 26 Jan 2026
) SRP-9001-301 PART-1. 3-Year Data Topline Results. Doug Ingram. Chief Executive Officer. Louise R. Rodino-Klapac, Ph.D ... DILLON ... ©SAREPTA THERAPEUTICS, INC. 2026 ... 1 ... ©SAREPTA THERAPEUTICS, INC. 2026 ... 3. ©SAREPTA THERAPEUTICS, INC. 2026 ... 3 ... Sarepta Therapeutics Inc.
Edit

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in ...

Business Wire 24 Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc.
Edit

Sarepta Reports Preliminaryx Fourth Quarter and Full-Year 2025 Net Product Revenues

Business Wire 13 Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc ... Morgan Healthcare Conference in San Francisco, California.
Edit

Sarepta Therapeutics 2026 JPMorgan Conference (Sarepta Therapeutics Inc)

Public Technologies 12 Jan 2026
Sarepta Therapeutics, Inc ... ©SAREPTA THERAPEUTICS, INC ... Strong Fundamentals Position Sarepta well into the Future. ©SAREPTA THERAPEUTICS, INC ... Strong Fundamentals Position Sarepta well into the Future. ©SAREPTA THERAPEUTICS, INC ... ©SAREPTA THERAPEUTICS, INC.
Edit

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Form 8-K) (Sarepta Therapeutics Inc)

Public Technologies 12 Jan 2026
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues • Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 ... 12, 2026 -- Sarepta Therapeutics, Inc.
Edit

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Sarepta Therapeutics Inc)

Public Technologies 12 Jan 2026
12, 2026-- Sarepta Therapeutics, Inc ... Sarepta's net product revenue does not include collaboration, contract manufacturing or royalty revenue ... You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Article Search

tools
×
×
×
×